New Delhi: The only Indian company Zydus Cadila which claims to have developed neutralising monoclonal antibodies (mAbs)-based cocktail for the treatment of Covid-19 has been given permission to conduct clinical trials by the Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO), according to sources.
“SEC gives a recommendation for the Phase I and II clinical trials of Zydus Cadila’s biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies (mAbs) that can emerge as one of the main treatments for mild Covid-19,” the sources said.
These antibodies are made by cloning unique white blood cells. Domestic pharmaceutical major Zydus Cadila sought the Drug Controller General of India (DCGI) permission recently to undertake clinical trials.
In recent years, diet and lifestyle have been recognized as crucial factors influencing cancer risk.…
Surgical advancements have evolved significantly over the decades, leading to improved precision, reduced recovery time,…
A tragic incident in northwest Delhi has sparked a medical negligence controversy after a 20-year-old…
Maharashtra is set to witness a significant transformation in its public health sector with the…
Sleep is essential for overall health, yet many people suffer from sleep disorders that disrupt…
Sleep is often regarded as a luxury in today’s fast-paced world, but scientific research continuously…